Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-24 @ 5:19 PM
Ignite Modification Date: 2025-12-25 @ 2:55 PM
NCT ID: NCT02289950
Term: Constipation
Organ System: Gastrointestinal disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA version 22.0
Notes: None
Study: NCT02289950
Study Brief: A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 93 58 141 View
EG001 53 31 70 View